Clinical trials: Respiratory Physiological Phenomena
Chronic Obstructive Pulmonary Disease
QVA Mechanistic Efficacy Study (Receptor Effects, Etc)
The purpose of this study was to assess global ventilated lung volume in moderate to severe COPD patients using MRI lung imaging after treatment with QVA149 compared to placebo.
- Trial name
- NCT02634983
- Testing
- QVA149
- Where
- 3 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Heart Disease Congenital Complex
Effect of Postop Steroids on Cardiovascular/Respiratory Function in Neonates Undergoing Cardiopulmonary Bypass
This protocol is designed to offer insight into critical illness related corticosteroid insufficiency and steroid supplementation in neonates undergoing cardiac surgery with cardiopulmonary bypass by administering exogenous…
- Trial name
- NCT01595386
- Testing
- Hydrocortisone, Normal Saline
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham
Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung function in subjects with COPD and a Low Peak…
- Trial name
- NCT03095456
- Testing
- Revefenacin, Spiriva Handihaler®
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Mylan Inc.
Pulmonary Disease, Chronic Obstructive
A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The primary purpose of this study is to evaluate lung function and health related quality of life (HRQoL) after 84 days of treatment with a single inhaler triple therapy combination of FF/UMEC/VI [100/62.5/25 microgram (mcg)]…
- Trial name
- NCT03478683
- Testing
- budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI
- Where
- 57 sites in United States, Czechia and 2 more
- Volunteers
- 729 people
- Sponsor
- GlaxoSmithKline
Bronchopulmonary Dysplasia
Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia
The purpose of this study is to determine if late doses of Infasurf surfactant given when patients are receiving inhaled nitric oxide will interact to improve surfactant function and increase survival without BPD in treated…
- Trial name
- TOLSURF (NCT01022580)
- Testing
- Infasurf surfactant (ONY, Inc.)
- Where
- 21 sites in United States
- Volunteers
- 511 people
- Sponsor
- Roberta Ballard
Airway Inflammation, Asthma
An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients
This is a randomised, active-comparator, open-label, parallel-group, multicentre phase IV exploratory study to characterise changes in airway inflammation, symptoms, lung function, and reliever use in asthma patients using SABA…
- Trial name
- NCT03924635
- Testing
- SYMBICORT and salbutamol
- Where
- 6 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Mild Persistent Asthma
Response of FeNO, Small Airway Dysfunction and Lung Heterogeneity to 2-week Montelukast Treatment in Asthmatic Children.
This study aims to identify markers to prove rapid improvement of lung function, airway inflammation and bronchodilator response after 2-week LTRA administration.
- Trial name
- NCT01581710
- Volunteers
- 32 people
- Sponsor
- CHA University
Diaphragm Paralysis
The Effect of Interscalene Peripheral Nerve Block With 0.25% Bupivacaine vs 0.125% Bupivacaine on Lung Function
Peripheral nerve blocks are used to provide post-operative pain relief. Nerve blocks in the neck, in the interscalene area, provide pain relief after shoulder surgery but can cause temporary weakness or paralysis of the…
- Trial name
- NCT01429584
- Testing
- interscalene nerve block with 0.25% bupivacaine, interscalene block with 0.125% bupivacaine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Utah
COVID-19, SARS-CoV 2
Canakinumab in Covid-19 Cardiac Injury (The Three C Study)
TThe purpose of this prospective, Phase 2, single center, blinded, randomized controlled study is to demonstrate as a proof of concept that early treatment with canakinumab prevents progressive heart and respiratory failure in…
- Trial name
- NCT04365153
- Testing
- Canakinumab Injection 600mg, Canakinumab Injection 300mg
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- The Cleveland Clinic
Hypertension, Pulmonary, Pulmonary Disease, Chronic Obstructive
Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of a single oral dose of BAY63-2521 in patients with pulmonary hypertension due to chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00640315
- Testing
- Riociguat (Adempas, BAY63-2521) 1.0 mg, Riociguat (Adempas, BAY63-2521) 2.5 mg
- Where
- 7 sites in Germany
- Volunteers
- 23 people
- Sponsor
- Bayer
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers
The primary objective of this study is to evaluate the efficacy and safety of orally inhaled tiotropium and olodaterol as both a fixed dose combination and a free combination with respect to lung function and ECG parameters
- Trial name
- NCT02030535
- Testing
- olodaterol, tiotropium
- Where
- 6 sites in Germany
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
This study was conducted to provide detailed information on the efficacy of indacaterol in terms of its effect on spirometry assessed forced expiratory volume in 1 second (FEV1) over a 24 hour time period.
- Trial name
- NCT00622635
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 14 sites in United States, Belgium and 1 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control
The study compared the 24-hour spirometry profile of indacaterol with that of placebo and with tiotropium as an active control in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00615459
- Testing
- Indacaterol, Tiotropium
- Where
- 20 sites in Australia, Germany and 5 more
- Volunteers
- 169 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)
This is a pilot study to investigate the effect of danirixin hydrobromide 35 milligram (mg) tablets on lung function and health related quality of life (HRQoL) in subjects with mild to moderate airflow obstruction and a…
- Trial name
- NCT03170232
- Testing
- Danirixin 35 mg tablets, Metered dose inhaler (MDI) sensor device, Rescue medication
- Where
- 11 sites in United States
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Lung Diseases, Interstitial
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic Pulmonary Fibrosis (IPF) can join the study.
- Trial name
- NCT05321082
- Testing
- BI 1015550
- Where
- 400 sites in United States, Argentina and 43 more
- Volunteers
- 1,178 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and suboptimal PIFR.
- Trial name
- PIFR-2 (NCT05165485)
- Testing
- Revefenacin, Tiotropium
- Where
- 76 sites in United States
- Volunteers
- 404 people
- Sponsor
- Theravance Biopharma
Pulmonary Disease, Chronic Obstructive
A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COPD is a progressive disease characterized by increasing obstruction to airflow and the progressive development of respiratory symptoms including chronic cough, increased sputum production, dyspnea and wheezing.
- Trial name
- NCT03474081
- Testing
- FF/UMEC/VI, Tiotropium, Albuterol/salbutamol
- Where
- 72 sites in United States, Poland and 1 more
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
This is a multicenter, prospective, randomized, double-blind, placebo-controlled trial that will enroll 1028 patients with at least moderately severe COPD over a three year period and follow them at regular intervals for one…
- Trial name
- NCT02587351
- Testing
- Metoprolol succinate
- Where
- 27 sites in United States
- Volunteers
- 532 people
- Sponsor
- University of Minnesota
Covid19, Respiratory Function Loss
Effect of Respiratory Exerciser on Pulmonary Functions of COVID-19 Patients
COVID-19 infection is the cause of the current pandemic, responsible for loss of life and disability at a rate unseen before. Among survivors, the infection may cause lasting damage, such as permanent loss of lung function.
- Conditions
- Covid19, Respiratory Function Loss, Coronavirus Infection, Pneumonia, Viral
- Trial name
- NCT04826731
- Testing
- Incentive Spirometer/Respiratory Exerciser
- Where
- Turkey (Türkiye)
- Volunteers
- 14 people
- Sponsor
- Diskapi Yildirim Beyazit Education and Research Hospital
Asthma
A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function
This study will be a repeat-dose, double-blind, randomized, placebo controlled, three-way crossover study in patients with persistent bronchial asthma to compare the effect of morning (AM) and evening (PM) dosing with fluticasone…
- Trial name
- NCT01287065
- Testing
- FF(100mcg)/Vilanterol(25mcg) AM, FF(100mcg)/Vilanterol(25mcg) PM
- Where
- New Zealand
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline